Decreased Proliferative Activity Associated with Activation Markers in Patients with Alcoholic Liver Cirrhosis
Overview
Affiliations
Peripheral blood mononuclear cells from 15 patients with alcoholic cirrhosis (AC) and 15 matched healthy controls were tested for their proliferative response to mitogens such as PHA and con A, tumour promoter PMA and OKT3 monoclonal antibody, for their capacity to produce IL-2 and to respond to recombinant IL-2 (rIL-2). The expression of IL-2 receptor (Tac) together with two other activation markers, the receptor for transferrin (T9) and Ia antigen have also been assessed. A profound decrease of proliferative response was observed after stimulation by lectins and PMA. IL-2 production was significantly decreased (0.39 +/- 0.07 versus 0.82 +/- 0.009 units; P less than 0.001) in alcoholic cirrhosis. Resting PBMC of these patients disclosed spontaneous responsiveness to rIL-2 without requiring prestimulation with PHA as observed in healthy subjects. This abnormal response was associated with significantly increased percentages of Tac (19.4 +/- 3.1 versus 5.1 +/- 1.1%; P less than 0.001), T9 (13.6 +/- 3.3 versus 6.6 +/- 1.1%; P = 0.04) and Ia positive cells (21.4 +/- 5.4 versus 11.5 +/- 1.4; P less than 0.05) in alcoholic cirrhosis. Defective proliferative activity and impaired IL-2 production, combined with an increase of lymphocytes bearing T cell activation markers and of rIL-2 responsiveness could represent in vitro correlates for mechanisms leading to immunoregulatory disturbances in cirrhotic patients.
Gromadzka G, Czerwinska J, Krzeminska E, Przybylkowski A, Litwin T Int J Mol Sci. 2024; 25(16).
PMID: 39201720 PMC: 11354778. DOI: 10.3390/ijms25169034.
Liver cirrhosis and immune dysfunction.
Hasa E, Hartmann P, Schnabl B Int Immunol. 2022; 34(9):455-466.
PMID: 35792761 PMC: 9447994. DOI: 10.1093/intimm/dxac030.
Lee D, Fan G, Hastie D, Prakasam V, Addonizio E, Ahern R J Clin Exp Hepatol. 2021; 11(5):531-543.
PMID: 34511813 PMC: 8414330. DOI: 10.1016/j.jceh.2021.01.005.
Inflammatory status in human hepatic cirrhosis.
Martinez-Esparza M, Tristan-Manzano M, Ruiz-Alcaraz A, Garcia-Penarrubia P World J Gastroenterol. 2015; 21(41):11522-41.
PMID: 26556984 PMC: 4631958. DOI: 10.3748/wjg.v21.i41.11522.
Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J Clin Exp Immunol. 1989; 77(2):221-5.
PMID: 2505958 PMC: 1541981.